Assessing Environmental Risks during the Drug Development Process for Parasitic Vector-Borne Diseases : A Critical Reflection
Parasitic vector-borne diseases (VBDs) represent nearly 20% of the global burden of infectious diseases. Moreover, the spread of VBDs is enhanced by global travel, urbanization, and climate change. Treatment of VBDs faces challenges due to limitations of existing drugs, as the potential for side effects in nontarget species raises significant environmental concerns. Consequently, considering environmental risks early in drug development processes is critically important. Here, we examine the environmental risk assessment process for veterinary medicinal products in the European Union and identify major gaps in the ecotoxicity data of these drugs. By highlighting the scarcity of ecotoxicological data for commonly used antiparasitic drugs, we stress the urgent need for considering the One Health concept. We advocate for employing predictive tools and nonanimal methodologies such as New Approach Methodologies at early stages of antiparasitic drug research and development. Furthermore, adopting progressive approaches to mitigate ecological risks requires the integration of nonstandard tests that account for real-world complexities and use environmentally relevant exposure scenarios. Such a strategy is vital for a sustainable drug development process as it adheres to the principles of One Health, ultimately contributing to a healthier and more sustainable world.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
ACS infectious diseases - 10(2024), 4 vom: 12. Apr., Seite 1026-1033 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ilbeigi, Kayhan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Drug development |
|---|
| Anmerkungen: |
Date Completed 15.04.2024 Date Revised 25.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1021/acsinfecdis.4c00131 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370232577 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370232577 | ||
| 003 | DE-627 | ||
| 005 | 20240425233322.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240328s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1021/acsinfecdis.4c00131 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1386.xml |
| 035 | |a (DE-627)NLM370232577 | ||
| 035 | |a (NLM)38533709 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ilbeigi, Kayhan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Assessing Environmental Risks during the Drug Development Process for Parasitic Vector-Borne Diseases |b A Critical Reflection |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.04.2024 | ||
| 500 | |a Date Revised 25.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Parasitic vector-borne diseases (VBDs) represent nearly 20% of the global burden of infectious diseases. Moreover, the spread of VBDs is enhanced by global travel, urbanization, and climate change. Treatment of VBDs faces challenges due to limitations of existing drugs, as the potential for side effects in nontarget species raises significant environmental concerns. Consequently, considering environmental risks early in drug development processes is critically important. Here, we examine the environmental risk assessment process for veterinary medicinal products in the European Union and identify major gaps in the ecotoxicity data of these drugs. By highlighting the scarcity of ecotoxicological data for commonly used antiparasitic drugs, we stress the urgent need for considering the One Health concept. We advocate for employing predictive tools and nonanimal methodologies such as New Approach Methodologies at early stages of antiparasitic drug research and development. Furthermore, adopting progressive approaches to mitigate ecological risks requires the integration of nonstandard tests that account for real-world complexities and use environmentally relevant exposure scenarios. Such a strategy is vital for a sustainable drug development process as it adheres to the principles of One Health, ultimately contributing to a healthier and more sustainable world | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a One Health | |
| 650 | 4 | |a drug development | |
| 650 | 4 | |a environmental risk | |
| 650 | 4 | |a parasitic vector-borne disease | |
| 700 | 1 | |a Barata, Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Barbosa, João |e verfasserin |4 aut | |
| 700 | 1 | |a Bertram, Michael G |e verfasserin |4 aut | |
| 700 | 1 | |a Caljon, Guy |e verfasserin |4 aut | |
| 700 | 1 | |a Costi, Maria Paola |e verfasserin |4 aut | |
| 700 | 1 | |a Kroll, Alexandra |e verfasserin |4 aut | |
| 700 | 1 | |a Margiotta-Casaluci, Luigi |e verfasserin |4 aut | |
| 700 | 1 | |a Thoré, Eli S J |e verfasserin |4 aut | |
| 700 | 1 | |a Bundschuh, Mirco |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ACS infectious diseases |d 2015 |g 10(2024), 4 vom: 12. Apr., Seite 1026-1033 |w (DE-627)NLM248280775 |x 2373-8227 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2024 |g number:4 |g day:12 |g month:04 |g pages:1026-1033 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1021/acsinfecdis.4c00131 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2024 |e 4 |b 12 |c 04 |h 1026-1033 | ||